Parkinson's Disease | Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids

Parkinson's Disease research study

What is the primary objective of this study?

The purpose of this research study is to measure the safety (side effects) of an Omega 3 Fatty acid called docosahexanoic acid (DHA) and measure the dyskinesia (involuntary movements) in Parkinson 's disease (PD).

Who is eligible to participate?

Inclusion Criteria: - Diagnosed with Parkinsons disease - No levodopa (Sinemet) treatment or prior exposure to levodopa Exclusion Criteria: - Prior exposure to levodopa - Unable to stand for 1 minute without aid - Sensory deficits on feet - Significant cognitive impairment - Current use of dopamine receptor blocking medications (depakote, lithium, amiodarone, tetrabenazine, metoclopramide, dronabinol) - Current fish oil or lutein supplementation - Allergy to soy

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Parkinson's Disease

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Docosahexaenoic Acid (DHA)Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years

Drug:PlaceboSugar Pill, taken for 1.5 years

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Arm 1Docosahexaenoic Acid (DHA)

Arm 2Placebo

Study Status


Start Date: October 2012

Completed Date: June 2016

Phase: Phase 1

Type: Interventional


Primary Outcome: Efficacy of DHA - Change in Blood ng/dL Levels

Secondary Outcome: Forceplate Measured Dyskinesia

Study sponsors, principal investigator, and references

Principal Investigator: Kathryn Anne Chung, MD

Lead Sponsor: VA Office of Research and Development

Collaborator: Oregon Health and Science University

More information:

Salem N Jr, Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids. 2001 Sep;36(9):945-59. Review.

P├ęchevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, Ziegler M; Trial Study Group. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005 Dec;12(12):956-63.

Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000 May 18;342(20):1484-91.

Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol. 2002 Jun;51(6):686-93.

Chung KA, Lobb BM, Nutt JG, McNames J, Horak F. Objective measurement of dyskinesia in Parkinson's disease using a force plate. Mov Disord. 2010 Apr 15;25(5):602-8. doi: 10.1002/mds.22856.

Discuss Dyskinesia